Literature DB >> 9422536

Deletion of Epstein-Barr virus latent membrane protein 1 gene in Japanese and Brazilian gastric carcinomas, metastatic lesions, and reactive lymphocytes.

K Hayashi1, W G Chen, Y Y Chen, I Murakami, H L Chen, N Ohara, S Nose, K Hamaya, S Matsui, M M Bacchi, C E Bacchi, K L Chang, L M Weiss.   

Abstract

A 30-bp deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) gene has been reported in nasopharyngeal carcinoma and EBV-associated malignant lymphomas. Information on this deletion in EBV-associated gastric carcinoma (EBVaGC) is limited. The association of gastric carcinoma (GC) with EBV was examined by EBV-encoded RNA (EBER) in situ hybridization in 510 patients from Japan and 80 patients from Brazil. We studied the prevalence of 30-bp LMP1 gene deletion in EBVaGC in Japan (29 cases) and Brazil (four cases) in comparison with the corresponding EBER1-positive metastatic lesions in lymph nodes (10 cases) and EBV-infected reactive lymphocytes from dissected nonmetastatic lymph nodes (22 cases), microdissected non-neoplastic gastric mucosa of EBVaGC (five cases), and EBV-nonassociated GC (25 cases). We studied the status of the LMP1 gene by Southern blot hybridization of polymerase chain reaction products obtained after amplification with primers flanking the site of the deletion. We also performed EBV typing and LMP1 protein immunohistochemistry. EBV DNA was amplified by polymerase chain reaction in 30 of 33 EBVaGC cases, 8 of 10 metastatic carcinomas, 14 non-neoplastic tissues from 27 EBVaGC cases, and 12 of 25 non-EBV-associated GC cases with EBER1-positive lymphocytes. The 30-bp LMP1 gene deletion was observed in 23 of 26 (88.5%) cases of EBVaGC from Japan and two of four (50%) cases of Brazilian EBVaGC as compared with EBER1-positive reactive lymphocytes from 11 of 14 (78.6%) EBVaGC cases and 9 of 12 (75%) cases of non-EBV-associated GC. The variant type (the 30-bp deletion variant or nondeleted wild type) of LMP1 gene was the same among reactive lymphocytes, primary and secondary lesions of EBVaGC in all cases for which all three tissue types were studied (six of six). There was no correlation between the presence of the 30-bp deletion with depth of cancer invasion or presence of metastasis. Type A was detected in all available EBV-positive cases. The similar high incidence of 30-bp deletion in LMP1 gene in both carcinoma cells and reactive lymphocytes in EBVaGC cases suggests that this deletion may not be relevant to the pathogenesis of EBVaGC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422536      PMCID: PMC1858103     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Detection of immunoglobulin light-chain mRNA in lymphoid tissues using a practical in situ hybridization method.

Authors:  L M Weiss; L A Movahed; Y Y Chen; S S Shin; R M Stroup; N Bui; P Estess; J M Bindl
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

2.  Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.

Authors:  S Henderson; M Rowe; C Gregory; D Croom-Carter; F Wang; R Longnecker; E Kieff; A Rickinson
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

3.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

Review 4.  Enzyme immunohistochemistry: technical aspects.

Authors:  K Sheibani; R R Tubbs
Journal:  Semin Diagn Pathol       Date:  1984-11       Impact factor: 3.464

5.  Low frequency of apoptosis in Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma.

Authors:  S Ohfuji; M Osaki; S Tsujitani; M Ikeguchi; T Sairenji; H Ito
Journal:  Int J Cancer       Date:  1996-12-11       Impact factor: 7.396

6.  Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction.

Authors:  A P Burke; T S Yen; K M Shekitka; L H Sobin
Journal:  Mod Pathol       Date:  1990-05       Impact factor: 7.842

Review 7.  Epstein-Barr virus in tumours.

Authors:  I Anagnostopoulos; M Hummel
Journal:  Histopathology       Date:  1996-10       Impact factor: 5.087

Review 8.  Epstein-Barr virus and gastric carcinoma.

Authors:  T Osato; S Imai
Journal:  Semin Cancer Biol       Date:  1996-08       Impact factor: 15.707

9.  Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.

Authors:  M Sugiura; S Imai; M Tokunaga; S Koizumi; M Uchizawa; K Okamoto; T Osato
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

10.  Epstein-Barr virus latent and replicative gene expression in gastric carcinoma.

Authors:  J Selves; F Bibeau; P Brousset; F Meggetto; C Mazerolles; J J Voigt; B Pradere; P Chiotasso; G Delsol
Journal:  Histopathology       Date:  1996-02       Impact factor: 5.087

View more
  10 in total

1.  Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1.

Authors:  Kyosuke Kanai; Yukio Satoh; Yuriko Saiki; Haruo Ohtani; Takeshi Sairenji
Journal:  Virus Genes       Date:  2006-08-18       Impact factor: 2.332

2.  Differential expression of apoptosis related proteins and nitric oxide synthases in Epstein Barr associated gastric carcinomas.

Authors:  Maria D Begnami; Andre L Montagnini; Andre L Vettore; Sueli Nonogaki; Mariana Brait; Alex Y Simoes-Sato; Andrea Q A Seixas; Fernando A Soares
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

3.  The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation.

Authors:  K M Izumi; E D Cahir McFarland; E A Riley; D Rizzo; Y Chen; E Kieff
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma.

Authors:  Lori Frappier; Vincent Ferretti; Ivan Borozan; Marc Zapatka
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

5.  Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations.

Authors:  P G Chu; K L Chang; W G Chen; Y Y Chen; D Shibata; K Hayashi; C Bacchi; M Bacchi; L M Weiss
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

6.  Epstein-Barr virus and gastric carcinoma--viral carcinogenesis through epigenetic mechanisms.

Authors:  Hiroshi Uozaki; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

7.  The full-length DNA sequence of Epstein Barr virus from a human gastric carcinoma cell line, SNU-719.

Authors:  Kyung-A Song; San-Duk Yang; Jinha Hwang; Jong-Il Kim; Myung-Soo Kang
Journal:  Virus Genes       Date:  2015-10-12       Impact factor: 2.332

8.  Evidence of Epstein-Barr virus association with gastric cancer and non-atrophic gastritis.

Authors:  Juan L E Martínez-López; Javier Torres; Margarita Camorlinga-Ponce; Alejandra Mantilla; Yelda A Leal; Ezequiel M Fuentes-Pananá
Journal:  Viruses       Date:  2014-01-20       Impact factor: 5.048

Review 9.  Epstein-barr virus sequence variation-biology and disease.

Authors:  Stelios Tzellos; Paul J Farrell
Journal:  Pathogens       Date:  2012-11-08

10.  Detection of Epstein-Barr virus in gastric adenocarcinoma: qPCR and FISH comparison.

Authors:  Igor Brasil-Costa; Carolina Rosal Teixeira de Souza; Iran Barros Costa; Liann Filiphe Pereira Dos Santos; Luana César Ferraz Paixão; Alessandra Alves Polaro; Talita Antonia Furtado Monteiro; Rommel Mario Rodríguez Burbano
Journal:  Med Microbiol Immunol       Date:  2021-12-03       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.